Abstract #1687

Characterization of a 5-HT2C Antagonist Profile of Agomelatine Using Challenge PhMRI in the Rat

Inna Linnik¹, Shane McKie², Jennifer A. Stark³, Simon Luckman³, Bill Deakin², Steve R. Steve R. Williams¹

¹Imaging Science and Biomedical Engineering, Manchester University, Manchester, UK; ²Neuroscience and Psychiatry Unit, Manchester University, Manchester, UK; ³Faculty of Life Science, Manchester University, Manchester, UK

Agomelatine is a novel clinically active antidepressant drug. The antidepressant activity of agomelatine needs the combination of melatonin agonist activity and 5-HT2C serotoninergic antagonist properties.